Home � Products & Services � Benchmarking Reports � Medical Affairs � Medical Affairs Excellence

Medical Affairs 2025: Where Are We Going? How Do We Get There?

Download FREE Excerpt

ID: POP-336

Features:

6 Info Graphics

28 Data Graphics

460+ Metrics

8 Narratives

Pages: 44

Published: 2021

Delivery Format: Shipped

License Options:
$5000 - 1 user
$15000 - Up to 5 users
$25000 - Up to 20 users

Buy Now

919-403-0251

Schedule a Meeting

STUDY OVERVIEW
BENCHMARK CLASS
STUDY SNAPSHOT
KEY FINDINGS
VIEW TOC AND LIST OF EXHIBITS

The last decade has seen Medical Affairs evolve from a support function to what many view as the third leadership pillar in biopharma. While the pace of change has significantly altered the healthcare landscape in the last few years, the Covid-19 pandemic has triggered a tsunami of rapid technology and role changes for Medical Affairs in particular.

While many of the fundamental trends will continue, the Medical Affairs function will also see new priorities and growth levels as we approach 2025.

Best Practices, LLC undertook this research to explore a four-year future horizon for Medical Affairs: What will the Medical Affairs organization look like in 2025? How will Medical Affairs leaders get there? The research examines evolving roles, stakeholder priorities, tools, technologies, capabilities, structures, rates of change, and top value fronts for this critical biopharma function.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Medical Device; Diagnostic; Health Care; Medical; Consulting; Consumer Products; Clinical Research; Laboratories

Companies Profiled:
AbbVie; Adamas Pharmaceuticals; Alkermes; Apellis Pharmaceuticals; ASC Therapeutics; Astellas; AstraZeneca; Aziyo Biologics; Inc.; Baxter Healthcare; BioMarin; bioMerieux; Boehringer Ingelheim; Castle Creek Biosciences; Cipla; Clovis Oncology; Eisai; Eli Lilly; EMD Serono; Gama PharMed Solutions Limited; Glenmark; Gossamer Bio; Greenwich Biosciences; Ipsen; Jazz Pharmaceuticals; Johnson & Johnson; Leica Biosystems; LEO Pharma; Lundbeck; Maxwell Clinic; MEDiSTRAVA; Melinta Therapeutics; Inc; Merck; Milestone Pharmaceuticals; Natera; NexGen Pharma; Novartis; Novavax; Novo Nordisk; Orion Pharmaceuticals; Pfizer; Partner Therapeutics (PTx); Regeneron; Roche; Sandoz; Sanofi; Sanofi Genzyme; Santen; Servier; Sunovion; Takeda Pharmaceuticals; Terumo Corporation; Teva Pharmaceutical Industries Ltd; United Therapeutics; Virbac; Zoetis Inc.

Study Snapshot

Best Practices, LLC developed a benchmark protocol that examines current and future Medical operations, capabilities, and performance. The study analysis engaged 74 executives from 57 leading life sciences companies. Chief Medical Officers and Medical Directors represent nearly 80% of the leaders who reflected on current Medical trends and future directions in this study.

Key topics covered in this report include:

Formula for Medical Affairs Excellence
Medical Affairs Priorities for 2025
Future Development in Medical Affairs
Medical’s Strategic Roles, Capabilities and Stakeholder Involvement
Medical Affairs Hybrid Workplace and Digital Transformation
Evidence Generation in 2025
Key Medical Affairs Responsibilities by 2025
Medical Affairs Value Communication
Optimizing Structure of Medical Affairs in 2025

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

Stakeholder Involvement: HCPs, Thought Leaders and Guideline Orgs. will remain key stakeholders. Payers, Advocacy Groups, Govt. Agencies, ACO/ IDNs, Pathway Vendors, Large employer groups & specialty pharmacies are high-growth areas headed towards 2025.

Digital Transformation: Post COVID, the majority of companies will use hybrid medical approaches for various group and functional roles. Digital technologies will extend reach, function and productivity across multiple groups within medical.

Evolution of RWE: Real world evidence is accelerating through technological advancements, greater payer focus, expanding MSL roles, and upgrading patient management pathways.

Table of Contents

Sr. No.	Topic	Slide No.
I.	Research Overview, Methodology & Participating Companies	Pg. 3
II.	Executive Summary	Pg. 4-5
III.	Medical Affairs Excellence: Moving to the Next Level by 2025	Pg. 6-9
IV.	Medical’s Strategic Roles, Capabilities & Stakeholder Involvement	Pg. 10-18
V.	Hybrid Workplace & Digital Transformation	Pg. 19-22
VI.	Evidence, Insights, Value and Structure	Pg. 23-30
VII.	Benchmark Class Profile	Pg. 31-33
VIII.	Detailed Benchmark Study Data	Pg. 34-43
IX.	About Best Practices, LLC	Pg. 44

List of Charts & Exhibits

I. Medical Affairs Excellence: Moving to the Next Level by 2025

Formula for excellence: Medical Affairs 2025 evolves and elevates five operational variables driving performance
Seven most important ranked priorities for Medical Affairs to achieve next level
Future Development in Medical Affairs

II. Medical’s Strategic Roles, Capabilities & Stakeholder Involvement

Current and future state of Medical Affairs’ leadership and support role
Important foundational Medical Affairs elements
External stakeholder groups with whom Medical Affairs works currently
External stakeholder groups with whom Medical Affairs will work in future
Importance and effectiveness of different external groups to the work conducted within the Medical Affairs organization
Importance and effectiveness of different external groups to the work conducted within Medical Affairs by 2025
Frequency of engagement of various Medical sub-functions with different external groups
Anticipated frequency of engagement of various Medical sub-functions with different external groups by 2025

III. Hybrid Workplace & Digital Transformation

Whether the concept of an office-based Medical Affairs employee is a thing of the past in the post-COVID era or not
Remote vs. office-based Medical Affairs post-COVID
Types of virtual capabilities being used / explored by benchmark organizations since the start of the COVID-19 pandemic

IV. Evidence, Insights, Value and Structure

Top Medical groups with greater importance in 2025, Top Medical groups with lesser importance in 2025
Evolution of evidence generation in 2025
Top roles undertaken by Medical Affairs to showcase value
Key responsibilities for Medical Affairs now and by 2025
Medical Affairs value communication
Optimizing structure of Medical Affairs in 2025
Medical group consolidation envisioned by leadership across key areas